PMID- 24724431
OWN - NLM
STAT- MEDLINE
DCOM- 20140520
LR  - 20140414
IS  - 0047-1860 (Print)
IS  - 0047-1860 (Linking)
VI  - 62
IP  - 1
DP  - 2014 Jan
TI  - [Future direction of pharmacogenomics: identification of genes associated with 
      risk of adverse drug reactions using genome-wide association study].
PG  - 83-8
AB  - Drug-induced skin rash characterized by an acute inflammatory reaction of skin 
      and mucous membranes is dose-independent, unpredictable, and sometimes 
      life-threatening. In recent years, the U.S. Food and Drug Administration (FDA) 
      has recommended genotyping of polymorphisms in the human leukocyte antigen (HLA) 
      prior to drug administration for the avoidance of severe skin rash induced by 
      drugs, such as abacavir and carbamazepine. A genome-wide association study (GWAS) 
      is useful for the identification of genomic biomarkers that can predict the 
      efficacy or risk of toxicity of various drugs. We identified novel susceptibility 
      loci associated with the risk of a skin rash induced by nevirapine and 
      carbamazepine in Thai and Japanese populations, respectively, through 
      case-control GWAS with high-throughput single-nucleotide polymorphism (SNP) 
      genotyping technology. In order to apply the genomic biomarkers to clinical 
      therapeutics, prospective clinical trials will be necessary for the evaluation of 
      an intervention based on genetic tests.
FAU - Mushiroda, Taisei
AU  - Mushiroda T
LA  - jpn
PT  - English Abstract
PT  - Journal Article
PT  - Review
PL  - Japan
TA  - Rinsho Byori
JT  - Rinsho byori. The Japanese journal of clinical pathology
JID - 2984781R
RN  - 0 (Anticonvulsants)
RN  - 0 (CCHCR1 protein, human)
RN  - 0 (Dideoxynucleosides)
RN  - 0 (HLA Antigens)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 33CM23913M (Carbamazepine)
RN  - 99DK7FVK1H (Nevirapine)
RN  - WR2TIP26VS (abacavir)
SB  - IM
MH  - Anticonvulsants/adverse effects
MH  - Carbamazepine/adverse effects
MH  - Dideoxynucleosides/administration & dosage
MH  - Drug Eruptions/*etiology/*genetics
MH  - Genetic Predisposition to Disease/*genetics
MH  - *Genome-Wide Association Study/methods
MH  - Genotyping Techniques
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/genetics
MH  - Nevirapine/adverse effects
MH  - Pharmacogenetics/*trends
MH  - Polymorphism, Genetic/genetics
MH  - Risk
EDAT- 2014/04/15 06:00
MHDA- 2014/05/21 06:00
CRDT- 2014/04/15 06:00
PHST- 2014/04/15 06:00 [entrez]
PHST- 2014/04/15 06:00 [pubmed]
PHST- 2014/05/21 06:00 [medline]
PST - ppublish
SO  - Rinsho Byori. 2014 Jan;62(1):83-8.